CAMBRIDGE, Mass., Aug. 14, 2017 /PRNewswire/ -- Merrimack
Pharmaceuticals (NASDAQ: MACK) today announced that it has
strengthened its executive management team with the appointment of
Jean M. Franchi as Chief Financial
Officer, effective August 21, 2017.
In this role, Ms. Franchi will plan and oversee Merrimack's
financial strategy to support the ongoing development of multiple
clinical- and preclinical-stage product candidates for cancer.
Over the course of a 30-year career in the biotechnology and
life sciences sectors, Ms. Franchi has held senior financial
management roles at several leading companies spanning all stages
of development, from research to commercial.
"Jean brings to Merrimack a wealth of experience managing
corporate finance and building strong public market support for
promising clinical development strategies," said Richard Peters, M.D., Ph.D., President and Chief
Executive Officer of Merrimack. "With Jean's appointment, along
with our other recent leadership additions, we have assembled a
strong executive team that will help us deliver on the tremendous
promise of our biomarker-focused development approach."
"I am pleased to join the world-class team at Merrimack as we
work together to propel the company to new heights, fueled by a
passion to deliver first-in-class precision solutions for cancer,"
said Ms. Franchi. "It is exciting to join a team with the
expertise, commitment and drive needed to successfully develop a
targeted pipeline designed to address specific cancer biology
problems."
Prior to joining Merrimack, Ms. Franchi most recently served as
the CFO for Dimension Therapeutics, where she was responsible for
all financial activities and related business strategy, including
the company's initial public offering in 2015. Previously, she was
the CFO at Good Start Genetics, a commercial-stage molecular
genetics information company focused on next-generation DNA
sequencing for rare diseases. Ms. Franchi also spent 16 years at
Genzyme (now Sanofi Genzyme), including as Senior Vice President of
Corporate Finance. Ms. Franchi holds a Bachelor's degree in
Business Administration from Hofstra
University.
About Merrimack
Merrimack is a biopharmaceutical
company based in Cambridge, Massachusetts that is
outthinking cancer to ensure that patients and their families live
fulfilling lives. Its mission is to transform cancer care through
the smart design and development of targeted solutions based on the
deep understanding of cancer pathways and biological markers. All
of Merrimack's product candidates, including three in clinical
studies and several others in preclinical development, fit into its
strategy of 1) understanding the biological problems it is trying
to solve, 2) designing specific solutions and 3) developing those
solutions for biomarker-selected patients. This three-pronged
strategy seeks to ensure optimal patient outcomes. For more
information, please visit Merrimack's website
at www.merrimack.com.
Forward Looking Statements
Any statements in this
press release about future expectations, plans and prospects for
Merrimack constitute forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995, as
amended. Actual results may differ materially from those indicated
by such forward-looking statements. Merrimack anticipates that
subsequent events and developments will cause its views to change.
However, while Merrimack may elect to update these forward-looking
statements at some point in the future, Merrimack specifically
disclaims any obligation to do so.
Contact:
Geoffrey
Grande, CFA
617-441-7602
ggrande@merrimack.com
View original
content:http://www.prnewswire.com/news-releases/merrimack-augments-executive-team-with-appointment-of-jean-franchi-as-chief-financial-officer-300503279.html
SOURCE Merrimack Pharmaceuticals